The Continuous Bioprocessing Technologies Market is projected to register a strong CAGR during the forecast period (2026-2031).
The continuous bioprocessing technologies market is growing with biopharma companies switching to continuous manufacturing for better efficiency, lower costs, and product quality enhancement over traditional batch processes. The increasing need for biologics, biosimilars, and vaccines is the main driver behind the adoption, which is also being supported by the regulatory push from the U.S. Food and Drug Administration and the European Medicines Agency. The market growth is also getting a push from the developments in automation, single-use systems, and real-time monitoring technologies.
The continuous bioprocessing technologies market is witnessing growth with an increasing number of biopharmaceutical manufacturers going away from traditional batch processing to integrated, continuous manufacturing systems in order to increase their productivity, lower their costs, and get better quality products. Continuous bioprocessing allows for a smooth production flow from one operation to the next in both upstream and downstream production, such as perfusion cell culture, continuous chromatography, in-line viral inactivation, and real-time quality monitoring. This not only speeds up production but also reduces the need for large production spaces.
The increasing need for monoclonal antibodies, biosimilars, vaccines, and other biologics is driving up the rate of adoption, especially among leading biopharmaceutical firms and contract development and manufacturing organizations (CDMOs) that are on the lookout for production platforms that are scalable and flexible. Besides that, regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency have been supportive of continuous manufacturing by releasing encouraging guidelines and pursuing further modernization, which has thus helped market momentum. Moreover, innovations in single-use systems, process analytical technologies (PAT), automation, and digital twins are enabling better process control and real-time release testing, which, in turn, are making continuous systems really viable for the market.
Increasing Demand for Cost-Effective Biosimilars: The patent expiries of biologics have resulted in a significant increase in biosimilar development worldwide. The manufacturers are compelled to lower their production costs without compromising on the quality and efficacy of their products. Continuous manufacturing offers the advantage of higher yield, better utilization of resources, and lower cost per gram of product; thus, it is considered very suitable to produce competitive biosimilars.
Transition from Batch to Integrated Continuous Manufacturing: Traditional batch bioprocessing is characterized by multiple hold steps, large intermediate storage requirements, and operational inefficiencies. Continuous systems overcome these issues by combining upstream and downstream operations into a single, uninterrupted process flow, which leads to shorter production cycles, less variability, and improved product consistency.
Regulatory Encouragement and Modernization Initiatives: Regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency have been promoting advanced manufacturing technologies by implementing various modernization programs, real-time release testing frameworks, and risk-based regulatory approaches. This alignment of regulations helps to reduce the level of uncertainty and thus makes it more attractive for pharmaceutical companies to invest in continuous systems.
Rising Investment by CDMOs and Biotech Startups: Contract Development and Manufacturing Organizations (CDMOs) are continuously increasing the adoption of continuous technologies to provide flexible and scalable manufacturing solutions. New biotech companies, which usually do not have their own production capabilities, thus choose to collaborate with CDMOs that have the latest continuous platforms.
High Initial Capital Investment and Infrastructure Costs: Transitioning from conventional batch manufacturing to fully integrated continuous bioprocessing requires a great deal of capital money upfront. Money must be spent on bioreactors, multi-column chromatography systems, automation platforms, process analytical technologies (PAT), and digital monitoring infrastructure. Refurbishing or redesigning the facilities adds to the expenses and thus becomes a financial hurdle for small and mid-sized biopharmaceutical firms.
Technical Complexity and Process Integration Challenges: Continuous processes depend on very close synchronization of upstream, downstream, and analytical operations. Controlling the process within the set limits of variables for longer production runs is very challenging and requires very advanced control strategies as well as a strong process design. If an operation breaks down in one unit, it will certainly affect the whole production line, raising the level of operational risk.
Limited Industry Experience and Skilled Workforce Shortage: Continuous bioprocessing involves expertise in automation, real-time analytics, data science, and bioprocess engineering. The limited availability of trained professionals with hands-on experience in continuous platforms restricts large-scale implementation and increases training costs.
Advancements in Automation, AI, and Digital Twin Technologies: The combination of artificial intelligence, predictive analytics, and digital twin modeling results in better process optimization and fewer operational risks. Due to these innovations, continuous systems are becoming more dependable and more commercially attractive.
June 2025: As part of their ongoing commitment to improving the delivery of materials to their customers who are developing and producing advanced therapies around the world, Cytiva (owned by Danaher) has undertaken substantial expansion projects at various facilities located throughout the United States, Europe, and Asia. Together, Cytiva has invested approximately USD 1.6 billion into these expansion programs since 2019.
May 2025: Thermo Fisher Scientific expanded its DynaDrive single-use bioreactor product series by introducing new sizes of bioreactors (such as 5-liter) that can handle continuous perfusion processes in the small to pilot-scale range, thereby enhancing scalability from development through production.
The market for Advanced Therapy Medicinal Products (ATMPs), including both cell and gene therapies, has grown faster than other molecule types. Due to the nature of how ATMPs are made, their manufacture must have a very specialized, scalable, and contamination-free production process, which is ideally suited for solution bioprocessing systems. The complexity of the production process, along with the increasing amount of regulatory support, the increased number of clinical trials, and the overall demand for new therapies, has led to a greater acceptance of the use of single-use bioreactors, perfusion culture systems, and integrated downstream purification technologies. Manufacturers can use continuous bioprocessing to achieve consistent product quality, optimize yield, and meet the exacting regulatory requirements placed on this new technology.
Continuous bioprocessing is a fast-growing segment of the biotechnology industry that is being driven by the need for CDMOs to develop new products faster, more consistently, and at lower cost. As a result of this demand for new products from clients in the market, CDMOs rely heavily on continuous bioprocessing technologies to create flexible, scalable, cost-effective production solutions that make it possible for small and medium-sized biotech companies to focus on their core business while allowing them to continue to make the necessary investments required to sustain their growth. By leveraging single-use and modular production technologies, CDMOs can respond very quickly to the changing requirements of their clients' manufacturing operations and simultaneously support the production of multiple product lines. As a result, CDMOs are becoming one of the largest segments of the continuous bioprocessing market globally.
North America is the biggest and most advanced market for continuous bioprocessing technologies. That is essentially because there are the top biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and a strong biotechnology ecosystem located in the United States and Canada. The U.S. Food and Drug Administration has given regulatory support and has even encouraged the adoption of continuous manufacturing through initiatives promoting Quality by Design (QbD) and Process Analytical Technology (PAT). The focus of the region on monoclonal antibodies, biosimilars, vaccines, and advanced therapy medicinal products (ATMPs) is also one of the factors that contribute to the growth of the market. Moreover, the availability of highly skilled professionals, cutting-edge infrastructure, and strong R&D investments has made North America the center for early adoption and innovation of integrated continuous manufacturing platforms.
Currently, there is an increased demand for biological products to treat various diseases, and this trend will continue and create new opportunities in the bioprocessing domain. Countries like Brazil, Argentina, and Mexico are making investments in the biopharmaceutical industry by encouraging local production of biosimilars and other biopharmaceuticals using bioreactors, which will help reduce reliance on imported products and improve healthcare systems. By providing an efficient method of producing biological pharmaceuticals with reduced footprints, companies will have better opportunities for success, especially if they have limited manufacturing resources.
Europe is one of the major regions for continuous bioprocessing technologies. Germany, Switzerland, France, and the United Kingdom are some of the countries that have been at the forefront of the industry. The location of large pharmaceutical and biotech companies, as well as supportive regulatory frameworks by the European Medicines Agency, makes it attractive for companies to adopt continuous manufacturing with an aim of ensuring consistent quality, and at the same time, reducing production costs.
European companies have been placing more emphasis on upgrading their facilities to be modular and more flexible through the introduction of single-use technologies combined with continuous upstream and downstream operations. Besides, measures for sustainability and environmental preservation go hand in hand with the energy-efficient and resource-optimized characteristics of continuous bioprocessing, thus boding well for the market in the region.
The Middle East and Africa are developing markets that have a large opportunity for growth with continuous bioprocessing technologies. Many countries in this region are making investments into healthcare infrastructure, biopharmaceutical manufacturing capabilities, and vaccine production facilities to decrease their dependency on imports and increase their ability to produce these materials within their own country.
Countries including the United Arab Emirates, Saudi Arabia, and South Africa are actively pursuing partnerships with global providers/developers of technology to implement continuous manufacturing systems. Although there is limited local expertise and the upfront costs to purchase machinery/equipment are also relatively high, there is a large opportunity for long-term growth when the continued growth in demand for cost-effective biologics/vaccines in this region is considered.
The demand for continuous bioprocessing technologies in the Asia-Pacific region continues to grow as the production of biopharmaceuticals increases, demand for additional healthcare services grows, and manufacturers receive support from governments to produce biological products within their own borders. Countries such as China, India, Japan, and South Korea have begun upgrading their manufacturing operations through investing in energy-efficient manufacturing facilities, such as single-use modular facilities that can meet both local and global needs for biosimilars and vaccine production. Factors driving adoption include cost-effectiveness, scalability, and the need to have short lead times for delivery. Further facilitating rapid adoption of continuous systems are the many strategic collaborations between local biotech companies and international providers of continuous system technologies, creating an extremely strong growth opportunity for the Asia-Pacific.
Thermo Fisher Scientific Inc.
Danaher Corporation
Sartorius AG
Merck KGaA
Repligen Corporation
WuXi Biologics
Eppendorf AG
Corning Incorporated
Entegris, Inc.
Getinge AB
Thermo Fisher Scientific Inc. provides a global solution for life science laboratories and development companies, but has also made advancements within the biopharmaceutical manufacturing space. Continuous bioprocessing includes multiple technology platforms that support both upstream and downstream operations through Thermo Fisher's portfolio of bioreactors, filtration systems, chromatography solutions, and automation systems. Biopharmaceutical manufacturers can use Thermo Fisher's technology platforms to maximize their production, minimize variation within their processes, and reduce the amount of time it takes to bring biologics, vaccines, and biosimilars to the market.
Danaher Corporation is a player in science and technology with a presence in continuous bioprocessing. They offer an extensive range of brands, including Pall Corporation and Cytiva, related to life sciences and biopharmaceutical manufacturing. As such, Danaher Corporation provides complete solutions for upstream (cell culture), downstream (purification; filtering), and single-use technologies that allow manufacturers to engage in real-time, scalable continuous bioprocessing. Danaher’s systems are intended to help increase productivity, improve consistency of the product quality, and lower operational costs for manufacturers of biological (biologic, biosimilar, vaccine) products.